Hospira Wins U.K.Challenge of Roche Cancer-Drug Patents
This article is for subscribers only.
Hospira Inc.’s U.K. unit won a court ruling overturning two patents for Roche Holding AG’s top-selling breast-cancer drug Herceptin, paving the way for the generic drug-maker to sell a cheaper competitor in the country.
The primary patent on Herceptin expires on July 28 in Europe. Lake Forest, Illinois-based Hospira was seeking to invalidate two additional protections that relate to the dosages and composition of the drug.